-
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
Source: Pharmafile Published on 2023-03-31
-
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Source: Pharmafile Published on 2023-03-31
-
Abbott gains FDA approval for Epic Max tissue valve for the treatment of aortic valve disease
Source: Pharmafile Published on 2023-03-31
-
First over-the-counter opioid overdose treatment approved by FDA
Source: Pharmafile Published on 2023-03-31
-
NEC streamlines AI drug development with subsidiary reshuffle
Source: Pharmafile Published on 2023-03-31
-
Nanoscope Therapeutics announces positive results from phase 2b trial in Retinitis Pigmentosa
Source: Pharmafile Published on 2023-03-31
-
Expansion of Scientific Affairs Group
Source: Pharmafile Published on 2023-03-30
-
Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases
Source: Pharmafile Published on 2023-03-30
-
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
Source: Pharmafile Published on 2023-03-30
-
PHARMANOVIA EXPANDS EXCLUSIVE LICENSING COLLABORATION WITH AQUESTIVE THERAPEUTICS FOR DIAZEPAM BUCCAL FILM
Source: Pharmafile Published on 2023-03-30
-
Unite Health: Thousands Honor Pandemic 'Influencers' Through COVID-19 Social Media Awards
Source: Pharmafile Published on 2023-03-30
-
UK and Polish regulatory authorities approve Akari Therapeutics’ higher-yielding manufacturing process
Source: Pharmafile Published on 2023-03-30
-
Hovione and Laxxon Medical sign partnership over 3D printed pharmaceutical applications
Source: Pharmafile Published on 2023-03-30
-
Janssen reports new Rybrevant data for patients with advanced non-small cell lung cancer
Source: Pharmafile Published on 2023-03-30
-
Alzheimer’s drug Leqembi expected to generate $12.9bn in sales by 2028
Source: Pharmafile Published on 2023-03-30